With a market capitalization (market cap) of $2.42B — a measure of how much the company is worth — Guardian Pharmacy Services, Inc. is the 1965th most valuable company in Healthcare as of August 19, 2026. Shares trade at $38.28, up +0.74% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider, delivering an extensive array of tech-driven solutions. These services are specifically crafted to enhance the care of residents within long-term health care facilities (LTCFs) across the United States. The company specializes in offering personalized clinical assistance, efficient drug distribution, and comprehensive administrative support. These provisions are particularly beneficial for individuals in less acute long-term care environments, such as assisted living communities, behavioral health centers, and group homes. To bolster its operations, the company offers Guardian Compass, a platform that generates insightful dashboards from its extensive data warehouse. This tool enables its network of local pharmacies to effectively strategize, monitor performance, and refine their business processes. Furthermore, Guardian Pharmacy Services develops dedicated GuardianShield Programs for LTCFs. The company was established in 2003 and is based in Atlanta, Georgia.
Visit websiteAs of August 19, 2026, Guardian Pharmacy Services, Inc. (GRDN) is worth $2.42B — this is its market capitalization, the total value of all its outstanding shares.
Guardian Pharmacy Services, Inc.’s market cap is $2.42B, which ranks it #1965 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Guardian Pharmacy Services, Inc. (GRDN) shares trade at $38.28, up 0.74% on the day, as of August 19, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025
Guardian Pharmacy Services, Inc. trades at a price-to-earnings (P/E) ratio of 48.5, based on its latest share price and annual earnings per share.